BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 16858680)

  • 1. Identification of HLA class I dependent immunogenic peptides from clonotypic TCRbeta expressed in cutaneous T-cell lymphoma.
    Zeng J; Müller-Berghaus J; Nguyen XD; Klüter H; Schönhaber H; Song M; Schwinn N; Schadendorf D; Goerdt S; Eichmüller S; Dippel E
    Int J Cancer; 2006 Nov; 119(10):2476-80. PubMed ID: 16858680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clonotypic T cell receptor is a source of tumor-associated antigens in cutaneous T cell lymphoma.
    Berger CL; Longley J; Hanlon D; Girardi M; Edelson R
    Ann N Y Acad Sci; 2001 Sep; 941():106-22. PubMed ID: 11594564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
    Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
    Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy.
    Ueda R; Ohkusu-Tsukada K; Fusaki N; Soeda A; Kawase T; Kawakami Y; Toda M
    Int J Cancer; 2010 Feb; 126(4):919-29. PubMed ID: 19728337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
    Edelson RL
    Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human T cell autoimmunity against myelin basic protein: CD4+ cells recognizing epitopes of the T cell receptor beta chain from a myelin basic protein-specific T cell clone.
    Saruhan-Direskeneli G; Weber F; Meinl E; Pette M; Giegerich G; Hinkkanen A; Epplen JT; Hohlfeld R; Wekerle H
    Eur J Immunol; 1993 Feb; 23(2):530-6. PubMed ID: 7679649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients.
    Scheibenbogen C; Lee KH; Mayer S; Stevanovic S; Moebius U; Herr W; Rammensee HG; Keilholz U
    Clin Cancer Res; 1997 Feb; 3(2):221-6. PubMed ID: 9815676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.
    Hundemer M; Schmidt S; Condomines M; Lupu A; Hose D; Moos M; Cremer F; Kleist C; Terness P; Belle S; Ho AD; Goldschmidt H; Klein B; Christensen O
    Exp Hematol; 2006 Apr; 34(4):486-96. PubMed ID: 16569595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.
    González FE; Ramírez M; Allerbring EB; Fasching N; Lundqvist A; Poschke I; Achour A; Salazar-Onfray F
    Immunobiology; 2014 Mar; 219(3):189-97. PubMed ID: 24192537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-specific peptides in cutaneous T-cell lymphoma: association with class I major histocompatibility complex and possible derivation from the clonotypic T-cell receptor.
    Berger CL; Longley BJ; Imaeda S; Christensen I; Heald P; Edelson RL
    Int J Cancer; 1998 May; 76(3):304-11. PubMed ID: 9579563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase.
    Vonderheide RH; Anderson KS; Hahn WC; Butler MO; Schultze JL; Nadler LM
    Clin Cancer Res; 2001 Nov; 7(11):3343-8. PubMed ID: 11705846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytolytic T-cell clones define HLA-A2-restricted human cutaneous melanoma peptide epitopes: correlation with T-cell receptor usage.
    Maeurer MJ; Hurd S; Martin DM; Storkus WJ; Lotze MT
    Cancer J Sci Am; 1995; 1(2):162-70. PubMed ID: 9166469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of HLA class I-restricted T-cell epitopes of islet autoantigen combined with binding and dissociation assays.
    Wu X; Xu X; Gu R; Wang Z; Chen H; Xu K; Zhang M; Hutton J; Yang T
    Autoimmunity; 2012 Mar; 45(2):176-85. PubMed ID: 22260783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen.
    Boss CN; Grünebach F; Brauer K; Häntschel M; Mirakaj V; Weinschenk T; Stevanovic S; Rammensee HG; Brossart P
    Clin Cancer Res; 2007 Jun; 13(11):3347-55. PubMed ID: 17545542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
    Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
    Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammaglobin-A is a tumor-associated antigen in human breast carcinoma.
    Tanaka Y; Amos KD; Fleming TP; Eberlein TJ; Goedegebuure PS
    Surgery; 2003 Jan; 133(1):74-80. PubMed ID: 12563241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients.
    Azuma K; Sasada T; Takedatsu H; Shomura H; Koga M; Maeda Y; Yao A; Hirai T; Takabayashi A; Shichijo S; Itoh K
    Clin Cancer Res; 2004 Oct; 10(19):6695-702. PubMed ID: 15475460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new nail in the CTCL coffin.
    Lessin SR
    J Invest Dermatol; 2006 Nov; 126(11):2368-9. PubMed ID: 17041618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
    Salgaller ML; Afshar A; Marincola FM; Rivoltini L; Kawakami Y; Rosenberg SA
    Cancer Res; 1995 Nov; 55(21):4972-9. PubMed ID: 7585538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Full-length dominant-negative survivin for cancer immunotherapy.
    Pisarev V; Yu B; Salup R; Sherman S; Altieri DC; Gabrilovich DI
    Clin Cancer Res; 2003 Dec; 9(17):6523-33. PubMed ID: 14695157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.